SoluneFit

Peptide library

CJC-1295 with DAC

Not FDA-approved Evidence grade B — human randomised trials, not approved for that use Updated 2026-10-20

This page describes published research and public regulatory records. It is not medical advice. SoluneFit does not sell, supply, or recommend any compound. The SoluneFit app includes a private, on-device tracker for people who want a record of what they and their clinician have already decided — the app neither suggests compounds nor doses.

Also known as: CJC-1295 DAC, CJC-1295 with Drug Affinity Complex, DAC:GRF, CJC-1295 DAC acetate.

Regulatory status

Not approved. At FDA's Pharmacy Compounding Advisory Committee on 4 Dec 2024 the committee voted 0-13 against placing each CJC-1295 form considered (free base, acetate, DAC free base, DAC acetate) on the 503A bulk-substances list, matching FDA's recommendation [4][3]. FDA lists CJC-1295 among substances previously in category 2 (significant safety risks: immunogenicity, increased heart rate, systemic vasodilatory reactions) whose nominations were withdrawn [5]. Not on the 503A bulk list, so it cannot lawfully be compounded from bulk under 503A.

What it is

Long-acting GHRH analogue (tetrasubstituted GRF(1-29) with a maleimide linker that binds serum albumin).

A modified GRF(1-29) built by ConjuChem to bind albumin in the blood, which stretches its action from minutes to about a week. Two small trials in healthy adults showed sustained rises in GH and IGF-1; development stopped after a death in an HIV-lipodystrophy trial, and it was never approved.

What the published research shows

Two randomised placebo-controlled ascending-dose trials in healthy adults aged 21-61 (Teichman 2006) plus a 12-man GH-pulsatility study (Ionescu 2006); a 192-patient HIV-lipodystrophy trial was stopped after a death and never published.

Published human studies and reports (these describe trial populations, not SoluneFit claims):

  • Healthy adults, single and repeated SC doses (Teichman 2006): Single SC doses of 30, 60, 125 or 250 µg/kg (study 1); repeated doses of 20-60 µg/kg weekly or every two weeks, 2-3 doses (study 2). Single doses raised mean GH 2-10-fold for 6 days or more and IGF-1 1.5-3-fold for 9-11 days; after repeated doses IGF-1 stayed above baseline for up to 28 days.
  • GH pulsatility in healthy men aged 20-40 (Ionescu & Frohman 2006): One SC injection of 60 or 90 µg/kg; one week later trough GH was 7.5-fold higher, mean GH +46 % and IGF-1 +45 %, with pulse frequency and size unchanged; no difference between the two doses.

Mechanism, as reported

Activates the GHRH receptor on the pituitary to release growth hormone, which raises IGF-1. The reactive linker attaches to albumin after injection, protecting it from breakdown; GH pulses are kept but trough GH rises sharply.

Practical record

  • Elimination half-life: 168.0 h (confidence: medium). Teichman 2006 estimated 5.8-8.1 days after single SC doses in healthy adults; the table uses ~7 days (168 h). Ionescu & Frohman 2006 quote 8 days.
  • Studied routes: subcutaneous.
  • Typical supply: Sold as lyophilised powder vials on the research-chemical market (no approved product).

Safety signals on record

  • Reported adverse events: In the healthy-volunteer trials most subjects on drug had adverse events: injection-site reactions (~70 %), headache, diarrhoea, and flushing / warmth / transient low blood pressure; flushing occurred in every subject at the higher repeated dose. Heart-rate increases were dose-dependent. One participant in the HIV-lipodystrophy trial died of a heart attack after his 11th weekly dose (investigator thought underlying coronary disease most likely).
  • Contraindications: None established (no label).
  • Interactions: None documented.
  • Notes: WADA Prohibited List 2026 (in force 1 Jan 2026), S2.2.4 names CJC-1295 among 'GHRH and its analogues', prohibited at all times (in and out of competition), non-specified. FDA's 2024 review also flagged genotoxicity signals in mouse pituitary, no carcinogenicity studies, and an antibody result it could not interpret [3]. Because it lasts about a week, effects (and side effects) of a dose cannot be stopped quickly.

Sources

  1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805 (2006)
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-7 (2006)
  3. FDA. Pharmacy Compounding Advisory Committee, 4 Dec 2024 — briefing document: CJC-1295-related bulk drug substances (free base, acetate, DAC free base, DAC acetate, DAC TFA) (2024)
  4. FDA. Pharmacy Compounding Advisory Committee, 4 Dec 2024 — meeting transcript, Topic 1: CJC-1295-related bulk drug substances (2024)
  5. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 under the 503A/503B interim policies; content current as of 22 Apr 2026) (2026)
  6. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-8 (2005)
  7. World Anti-Doping Agency. The 2026 Prohibited List (International Standard), in force 1 January 2026 — section S2.2.4 Growth hormone releasing factors (S2.2.4 text checked against a mirrored copy of this PDF; wada-ama.org blocked automated download) (2025)

General wellness education, not medical advice. Unapproved compounds have no established dosing, purity standard, or safety profile.

← All compounds